MRG007

ARR-217 · ArriVent BioPharma, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MRG007, covering 2026-02-17 to 2026-02-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors [Phase 1]